EP1108436A4 - Preventives/remedies for arteriosclerosis and post-ptca reangiostenosis - Google Patents

Preventives/remedies for arteriosclerosis and post-ptca reangiostenosis

Info

Publication number
EP1108436A4
EP1108436A4 EP99938605A EP99938605A EP1108436A4 EP 1108436 A4 EP1108436 A4 EP 1108436A4 EP 99938605 A EP99938605 A EP 99938605A EP 99938605 A EP99938605 A EP 99938605A EP 1108436 A4 EP1108436 A4 EP 1108436A4
Authority
EP
European Patent Office
Prior art keywords
ptca
arteriosclerosis
reangiostenosis
preventives
remedies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP99938605A
Other languages
German (de)
French (fr)
Other versions
EP1108436B1 (en
EP1108436A1 (en
Inventor
Takashi Muramatsu
Kenji Kadomatsu
Mitsuru Horiba
Shinya Ikematsu
Sadatoshi Sakuma
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Anagenics Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP1108436A1 publication Critical patent/EP1108436A1/en
Publication of EP1108436A4 publication Critical patent/EP1108436A4/en
Application granted granted Critical
Publication of EP1108436B1 publication Critical patent/EP1108436B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Abstract

The present invention provides a pharmaceutical composition for the prevention or treatment of angiostenosis, comprising a compound inhibiting the function of midkine (MK) in blood vessel tissues as an effective ingredient. The present invention is useful for the prevention or treatment of angiostenosis attributed to arteriosclerosis or restenosis after percutaneous transluminal coronary angioplasty (PTCA). As compounds inhibiting the function of MK, antisense oligonucleotides that bind to a segment of a single-stranded mRNA transcribed from the MK gene to inhibit the synthesis of MK protein in cells, antibodies against the MK protein, and such can be used.
EP99938605A 1998-08-24 1999-08-24 Pharmaceutical compositions for the prevention and treatment of atherosclerosis and restenosis after ptca Expired - Lifetime EP1108436B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP25181298 1998-08-24
JP25181298 1998-08-24
PCT/JP1999/004550 WO2000010608A1 (en) 1998-08-24 1999-08-24 Preventives/remedies for arteriosclerosis and post-ptca reangiostenosis

Publications (3)

Publication Number Publication Date
EP1108436A1 EP1108436A1 (en) 2001-06-20
EP1108436A4 true EP1108436A4 (en) 2002-05-29
EP1108436B1 EP1108436B1 (en) 2009-08-12

Family

ID=17228295

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99938605A Expired - Lifetime EP1108436B1 (en) 1998-08-24 1999-08-24 Pharmaceutical compositions for the prevention and treatment of atherosclerosis and restenosis after ptca

Country Status (10)

Country Link
US (2) US7309695B2 (en)
EP (1) EP1108436B1 (en)
JP (1) JP4228111B2 (en)
KR (1) KR100608276B1 (en)
CN (1) CN1222296C (en)
AT (1) ATE439146T1 (en)
AU (1) AU762437B2 (en)
CA (1) CA2341638C (en)
DE (1) DE69941263D1 (en)
WO (1) WO2000010608A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109799126A (en) * 2014-07-25 2019-05-24 立佳有限公司 Dilute the analysis method of biological specimen ingredient

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8106009B2 (en) * 1997-09-26 2012-01-31 Medical Therapies Limited Pharmaceutical composition for preventing or treating ischemic diseases
US8221758B2 (en) 2003-03-06 2012-07-17 Cellmid Limited Anti-midkine antibody for preventing post-laparotomy adhesions
US20060085062A1 (en) * 2003-11-28 2006-04-20 Medlogics Device Corporation Implantable stent with endothelialization factor
CN100434521C (en) * 2004-12-28 2008-11-19 湖州市中心医院 Structure and application of antisense oligonucleotide with gene of mid-range factor as target
EP1900380B1 (en) * 2005-05-25 2013-03-27 Cellmid Limited Pharmaceutical composition for vascular occlusive disease
US8080649B2 (en) 2006-11-14 2011-12-20 Ribomic Inc. Aptamer against midkine and use thereof
JP5663137B2 (en) 2006-11-14 2015-02-04 セルミド リミテッド Antibody recognizing midkine C-domain
EP2686016B1 (en) 2011-03-14 2019-05-01 Cellmid Limited Antibody recognizing n-domain of midkine
US9840552B2 (en) 2012-07-30 2017-12-12 National University Corporation Nagoya University Monoclonal antibody against human midkine
GB2582457B (en) 2017-08-25 2021-02-24 Stoke Therapeutics Inc Antisense oligomers specific for SCN1A

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH079641A (en) * 1993-04-16 1995-01-13 Wolff Walsrode Ag Oriented film that is reduced in reflection and can be bonded with suitability for envelope window film
WO1996002257A1 (en) * 1994-07-18 1996-02-01 Georgetown University Antisense oligonucleotides of pleiotrophin
WO1999038971A1 (en) * 1998-02-02 1999-08-05 Meiji Milk Products Co., Ltd. Protein binding to midkine

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993008828A1 (en) 1991-11-08 1993-05-13 Syntex-Synergen Neuroscience Joint Venture Methods for the treatment of neuronal damage associated with ischemia, hypoxia or neurodegeneration
ATE340590T1 (en) * 1994-07-13 2006-10-15 Chugai Pharmaceutical Co Ltd RECONSTITUTED HUMAN ANTIBODY DIRECTED AGAINST HUMAN INTERLEUKIN-8
US6048972A (en) * 1994-07-13 2000-04-11 Chugai Pharmaceutical Co., Ltd. Recombinant materials for producing humanized anti-IL-8 antibodies
JPH0827021A (en) * 1994-07-22 1996-01-30 Mitsui Toatsu Chem Inc Medicinal composition
JP3553655B2 (en) * 1994-09-02 2004-08-11 喬 村松 Method for producing polypeptide
US5670477A (en) 1995-04-20 1997-09-23 Joseph F. Poduslo Method to enhance permeability of the blood/brain blood/nerve bariers to therapeutic agents
US5629284A (en) 1995-07-24 1997-05-13 Meiji Milk Products Co., Ltd. Method for treating retinal diseases
JPH0995454A (en) 1995-10-02 1997-04-08 Meiji Milk Prod Co Ltd Antiulcerative composition
ATE330620T1 (en) 1997-07-14 2006-07-15 Takashi Muramatsu USE OF MIDKIN OR ANTI-MIDKIN ANTIBODIES
CN1278184A (en) * 1997-09-26 2000-12-27 吉田义弘 Preventives or remedies for ischemic diseases
US8106009B2 (en) 1997-09-26 2012-01-31 Medical Therapies Limited Pharmaceutical composition for preventing or treating ischemic diseases
DE59802178D1 (en) 1997-12-23 2001-12-20 Schleuniger Holding Ag Thun INSULATING DEVICE

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH079641A (en) * 1993-04-16 1995-01-13 Wolff Walsrode Ag Oriented film that is reduced in reflection and can be bonded with suitability for envelope window film
WO1996002257A1 (en) * 1994-07-18 1996-02-01 Georgetown University Antisense oligonucleotides of pleiotrophin
WO1999038971A1 (en) * 1998-02-02 1999-08-05 Meiji Milk Products Co., Ltd. Protein binding to midkine

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
E. A. RATOVITSKI ET AL.: "Midkine induces tumor cell proliferation and binds to a high affinity signaling receptor associated with JAK tyrosine kinases", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 273, no. 6, 6 February 1993 (1993-02-06), pages 3654 - 3660, XP002920158 *
H. MURAMATSU ET AL.: "Enzyme-linked immunoassay for midkine, and its application to evaluation of midkine levels in developing mouse brain and sera from patients with hepatocellular carcinomas", J. BIOCHEM., vol. 119, no. 6, 1996, pages 1171 - 1175, XP002194269 *
PATENT ABSTRACTS OF JAPAN vol. 2000, no. 17 5 June 2001 (2001-06-05) *
SHA-YAN WANG ET AL.: "Midkine exists in astrocytes in the early stage of cerebral infarction", DEVELOPMENTAL BRAIN RESEARCH, vol. 106, 1998, pages 205 - 209, XP002933220 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109799126A (en) * 2014-07-25 2019-05-24 立佳有限公司 Dilute the analysis method of biological specimen ingredient

Also Published As

Publication number Publication date
CN1324249A (en) 2001-11-28
KR20010103572A (en) 2001-11-23
EP1108436B1 (en) 2009-08-12
CA2341638C (en) 2010-05-11
WO2000010608A1 (en) 2000-03-02
US7309695B2 (en) 2007-12-18
US20080107659A1 (en) 2008-05-08
AU5305599A (en) 2000-03-14
US20040077579A1 (en) 2004-04-22
CA2341638A1 (en) 2000-03-02
JP4228111B2 (en) 2009-02-25
EP1108436A1 (en) 2001-06-20
ATE439146T1 (en) 2009-08-15
AU762437B2 (en) 2003-06-26
DE69941263D1 (en) 2009-09-24
US7820160B2 (en) 2010-10-26
KR100608276B1 (en) 2006-08-02
CN1222296C (en) 2005-10-12

Similar Documents

Publication Publication Date Title
DK0810889T3 (en) implant
ATE556705T1 (en) PHARMACEUTICAL FORM CONTAINING TAXOL IN CRYSTALLINE FORM
CA2285389A1 (en) Use of cytoskeletal inhibitors for the prevention of restenosis
EP1108436A4 (en) Preventives/remedies for arteriosclerosis and post-ptca reangiostenosis
BG103793A (en) COMBINED THERAPY USING BENZOTHIAPINS INHIBITING THE ILEAL BILE ACID TRANSPORT AND HMG Co-A REDUCTASE INHIBITORS
WO2003070283A3 (en) Agent for inhibiting development or progress of proliferative diseases and especially cancer diseases and pharmaceutical composition containing said agent
EP2223922A3 (en) Inhibitors of human phosphatidyl-inositol 3-kinase delta
MXPA03011680A (en) Film-forming compositions for protecting skin from body fluids and articles made therefrom.
CA2267186A1 (en) Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia
UA35589C2 (en) INHIBITORS OF TESTOSTERONE 5-<font face="Symbol">a</font>-REDUCTASE activity, pharmaceutical composition and a method for inhibiting activity of testosterone 5-<font face="Symbol">a</font>-REDUCTASE
NZ294933A (en) Thienopyridine or thienopyrimidine derivatives, pharmaceutical compositions and use as anti-inflammatory agents
DE69431517D1 (en) HYPOLIPEMIC COMPOUNDS
SI1349847T1 (en) Oxybenzamides derivatives as factor xa inhibitors
ZA9610543B (en) Compounds and compositions for reducing blood glucose and/or inhibiting the activity of CGRP.
MXPA01010588A (en) Medicaments containing inhibitors of cell-volume regulated human kinase h-sgk.
WO2002040481A3 (en) Adenine based inhibitors of adenylyl cyclase, pharmaceutical compositions and method of use thereof
HK1055941A1 (en) Factor viia inhibitory (thio) urea derivatives, their preparation and their use.
WO2000071516A3 (en) INHIBITORS OF FACTOR Xa
WO1998036730A3 (en) Compositions for treating acne rosacea
WO1999012933A3 (en) Pyrrolopyrrolone derivatives as inhibitors of neutrophil elastase
MX9709451A (en) Benzisoxazole and indazole derivatives as antipsychotic agents.
DE69821749D1 (en) BENZIMIDAZOLE DERIVATIVES AND THEIR COMPATIBLE SALTS
EP0733640A4 (en) Double-stranded oligonucleotide and carcinostatic agent containing the same as active ingredient
TW363051B (en) Substituted amidine derivatives and platelet aggregation inhibitor containing the same
WO2005039629A3 (en) Caspase inhibitors as coating materiel for medical products for inhibiting restenosis

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010323

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: MURAMATSU, TAKASHI

A4 Supplementary search report drawn up and despatched

Effective date: 20020417

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 61K 45/00 A, 7A 61K 48/00 B, 7A 61K 31/70 B, 7C 12N 15/19 B, 7A 61K 39/395 B

17Q First examination report despatched

Effective date: 20040114

17Q First examination report despatched

Effective date: 20040114

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: MEDICAL THERAPIES LIMITED

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 9/10 20060101ALI20090203BHEP

Ipc: A61K 39/395 20060101ALI20090203BHEP

Ipc: C12N 15/19 20060101ALI20090203BHEP

Ipc: A61K 31/70 20060101ALI20090203BHEP

Ipc: A61K 48/00 20060101ALI20090203BHEP

Ipc: A61K 45/00 20060101AFI20090203BHEP

RTI1 Title (correction)

Free format text: PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF ATHEROSCLEROSIS AND RESTENOSIS AFTER PTCA

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 69941263

Country of ref document: DE

Date of ref document: 20090924

Kind code of ref document: P

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: FREI PATENTANWALTSBUERO AG

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090812

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090812

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20091123

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090812

NLV1 Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090812

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20091212

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090831

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090812

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090812

26N No opposition filed

Effective date: 20100517

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090824

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20091113

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090812

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090824

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090812

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20150826

Year of fee payment: 17

Ref country code: DE

Payment date: 20150824

Year of fee payment: 17

Ref country code: CH

Payment date: 20150813

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20150831

Year of fee payment: 17

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 69941263

Country of ref document: DE

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20160824

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160831

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160831

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20170428

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160824

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160831

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170301